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Abstract
Background: Single nucleotide polymorphisms (SNPs) in the dhfr and dhps genes are associated with sulphadoxine-
pyrimethamine (SP) treatment failure and gametocyte carriage. This may result in enhanced transmission of mutant malaria
parasites, as previously shown for chloroquine resistant parasites. In the present study, we determine the association
between parasite mutations, submicroscopic P. falciparum gametocytemia and malaria transmission to mosquitoes.
Methodology/Principal Findings: Samples from children treated with SP alone or in combination with artesunate (AS) or
amodiaquine were genotyped for SNPs in the dhfr and dhps genes. Gametocytemia was determined by microscopy and
Pfs25 RNA–based quantitative nucleic acid sequence–based amplification (Pfs25 QT-NASBA). Transmission was determined
by membrane-feeding assays. We observed no wild type infections, 66.5% (127/191) of the infections expressed mutations
at all three dhfr codons prior to treatment. The presence of all three mutations was not related to higher Pfs25 QT-NASBA
gametocyte prevalence or density during follow-up, compared to double mutant infections. The proportion of infected
mosquitoes or oocyst burden was also not related to the number of mutations. Addition of AS to SP reduced
gametocytemia and malaria transmission during follow-up.
Conclusions/Significance: In our study population where all infections had at least a double mutation in the dhfr gene,
additional mutations were not related to increased submicroscopic gametocytemia or enhanced malaria transmission. The
absence of wild-type infections is likely to have reduced our power to detect differences. Our data further support the use of
ACT to reduce the transmission of drug-resistant malaria parasites.
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Introduction
Artemisinin-based combination therapy (ACT) is now widely
advocated as first-line antimalarial treatment. Nevertheless, drugs
that are now no longer recommended as first-line treatment, such as
sulphadoxine-pyrimethamine (SP), will continue to play a role in
malaria control. A change in international therapeutic recommen-
dations is not always translated into an immediate, effective policy
change at country levels. In Kenya, monotherapy with chloroquine
was replaced by SP in 1998 and SP was officially replaced by the
ACT Artemether-Lumefantrine (AL) in 2004 [1]. However, health
worker training and distribution of AL were not completed until the
end of 2006 [1]. Even if official recommendations are followed by
government services, monotherapy will remain available in the
private sector, as was reported in Nigeria [2]. Furthermore, SP also
plays an important role in intermittent preventive treatment to
controlmalariaininfants[3,4]and pregnantwomen[5]and insome
situations the combination of SP with amodiaquine (AQ) may be a
cheap and efficacious alternative to ACT [6,7]. The ongoing use of
SP, either in treatment of uncomplicated malaria or as method of
malaria control by intermittent preventive treatment, underlines the
importance of continued studies of SP resistance and the way
resistance spreads in populations.
SP resistance is associated with the presence of single nucleotide
polymorphisms (SNPs) in the dhfr and dhps genes [8–10]. This SP
resistance starts off with a core SNP at codon 108 (S108N), which
is followed by mutations at c51 (N51I) and 59 (C59R) [11] leading
to a so-called ‘triple mutation’. Additional mutations in the dhps
gene (codon 437 and 540) are related with even higher risks for SP
treatment failure [12]. Other codons (in dhfr at c164 and dhps at
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Southeast Asia [13,14] and Latin America [9], but until now, these
mutations are uncommon on the African continent and have
rarely been found in East Africa [15–19].
The presence of mutations in the dhfr and dhps genes may not
only predict treatment outcome, but may also be related to the
transmission stages of P. falciparum, the gametocytes. The presence
of resistant parasites at enrolment was found to be related to
microscopically detected gametocytes during follow-up [20,21] or
even prior to treatment [21] and to the duration of gametocyte
carriage [22]. Mutations in the Pfcrt and Pfmdr1 genes, encoding
CQ resistance, were associated with a higher gametocyte density
and subsequent malaria transmission after CQ monotherapy
[23,24] or SP/CQ combination treatment [25]. Recently, a study
of Me ´ndez and others showed that in Colombia, malaria
transmission was enhanced for parasites with low levels of
resistance to SP compared to fully sensitive parasites [26]. In
addition to a transmission advantage of mutant parasites in the
human host through a higher gametocyte prevalence or density
[20,23], there may also be a selective advantage in the mosquito
midgut, as was suggested for Pfcrt mutations [23]. These findings
are worrying, indicating a very rapid spread of mutant parasites
under drug pressure, but need confirmation in areas with different
levels of transmission intensity and drug resistance.
Molecular gametocyte detection tools have recently demon-
strated that gametocyte carriage can be seriously underestimated
by the use of microscopy [27]. Submicroscopic gametocytes are
not only common in various populations [27–29], but may also
contribute considerably to malaria transmission [27].
The present study was conducted in an area of high resistance to
SP with more than 50% treatment failure within one month of
follow-up [27]. Samples from a previously published study on
submicroscopic gametocytemia following antimalarial treatment
[27] were genotyped to determine the relation between parasite
mutations, submicroscopic gametocytemia and the transmission of
malaria to mosquitoes.
Methods
Ethics statement
The study protocol (SSC No. 791) was approved by the Scientific
Steering Committee and Ethical Review Committee of the Kenya
Medical Research Institute. Written, informed consent was obtained
from a parent orguardian ofthe participating children.The trial was
completed in 2004, before registration became mandatory for
clinical trials. The trial was registered after completion under
Clinical Trials registration number ISRCTN31291803 (http://
www.controlled-trials.com/ISRCTN31291803).
Objectives
We hypothesized that mutant parasites possess a transmission
advantage compared to susceptible parasites. To test this hypothesis,
our primary objectives were to determine the number of allelic
variants before and after treatment and to determine the relation
between mutations in the dhfr and dhps genes and: i) gametocyte
prevalence and density by microscopy and RNA-based quantitative
nucleic acid sequence based amplification (QT-NASBA); ii)
mosquito infection rates; iii) oocyst densities in mosquitoes.
Participants
This study was conducted from October to December 2004
(short rainy season) in Mbita, a rural village on the shores of Lake
Victoria in Suba District, western Kenya. The main malaria
vectors in the area are A. gambiae, A. funestus, and A. arabiensis.
Malaria transmission is high and perennial, with parasite
prevalences in the human population ranging from 24.4% to
99.0%. Generally, the rainfall pattern is bimodal, with a long rainy
season between March and May and a short rainy season between
October and December.
The study population and treatment procedures are described
elsewhere [27]. Briefly, 528 children (6 months–10 years) with P.
falciparum mono-infection with a minimum parasite density of 500/
parasitesmL,feverorhistoryoffeverinthelast48 hoursandabsence
of danger signs were enrolled and randomised to treatment with
sulphadoxine-pyrimethamine (SP; FansidarH,R o c h e ,S w i t z e r l a n d ) ,
SP plus amodiaquine (AQ; CamoquineH, Pfizer, Senegal), SP +
Artesunate (AS; ArsumaxH, Sanofi, France) or Artemether-Lume-
fantrine (AL; CoArtemH, Novartis Pharma, Switzerland). Samples
wererandomlyselectedfromthestudypopulationsof2003and2004
for molecular analysis of gametocyte carriage [27]. In addition, a
random selection of 25 children per treatment arm was invited for
membrane feeding experiments and molecular analysis of gameto-
cyte carriage, irrespective of gametocyte carriage status [27].
Samples from these two groups were combined and used for
parasitegenotyping in the current study.Onlychildrenwhoreceived
SP alone or in combination with AQ or AS were included in the
current study because we were interested in the transmission
potential in relation to mutations in the dhfr and dhps genes (i.e.
mutations that are associated with SP treatment failure). In addition,
we determined the prevalence of mutations in the Pfcrt gene that are
associated with AQ treatment failure.
Description of procedures
Microscopy and Pfs25 QT-NASBA. Blood smears were
stained with 10% Giemsa for 10 min and then screened for
asexual parasites and gametocytes at enrolment and on days 3, 7,
14, and 28. Asexual parasites and gametocytes were counted
against 200 and 500 white blood cells (WBCs), respectively, and
the counts were converted to parasites per microliter on the
assumption of a density of 8000 WBCs/mL. Parasite detection by
Pfs25 QT-NASBA was done at day 0, 3, 7, 14 and 28 as described
elsewhere [30,31], using a NucliSens EasyQ analyser (bioMe ´rieux)
as described elsewhere for Pfs25 mRNA [30]. Nucleic acids were
extracted from 50-mL blood samples as described by Boom and
others [32]. The Pfs25 QT-NASBA technique is gametocyte
specific and has a detection limit of 0.02–0.1 gametocytes/mL.
NucliSens Basic kits were used for amplification, in accordance
with the manufacturer’s instructions. A standard dilution series of
mature, in vitro–cultured NF54 gametocytes [33] was included in
each run to determine gametocyte densities in the test samples.
Mosquito membrane feeding and dissection. Membrane-
feeding assays were conducted on day 14 after treatment, as
described elsewhere [27]. Briefly, 3-mL venous blood samples
were obtained and fed to ,150 locally reared [34] 4–5-day-old
female A. gambiae sensu stricto mosquitoes via an artificial
membrane attached to a water-jacketed glass feeder maintained
at 37uC. After 10–15 minutes, fully fed mosquitoes were selected
and kept on glucose for 7 days at 27uC–29uC, at which time
midguts were dissected in 2% mercurochrome. Midguts were
examined microscopically for oocysts, with a second microscopist
confirming their presence if observed. Exactly 30 mosquitoes were
dissected per child.
Detection of SNPs in dhfr/dhps and Pfcrt by PCR and
SSOP-ELISA. Samples collected at patient enrolment were
screened for SNPs at dhfr c108, c59 and c51, using PCR-SSOP
as previously described [25,35] and provided an estimate of
baseline allele frequencies at this locus. Samples from individuals
participating in membrane feeding experiments were more
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these samples, SNPs at dhfr (at c50/51, c59, c108 and c164), dhps
(at c436/437, c540, c581 and c613) and Pfcrt (position 72–76) were
determined by SSOP-ELISA of PCR amplified fragments using
conditions and reagents as described by Alifrangis and others [36].
For each SNP analyses, parasite samples were categorized into
single, mixed but with one SNP in majority or mixed infections with
no SNP in majority as described by Alifrangis and others [36]. The
mixed samples with one SNP in majority were considered as single
mutations. All SSOP-ELISA data were divided into wild or mutant
type; samples with a mixed infection (wild-type and mutant) were
considered as mutant. Samples with a mutation in c108+c59 or
c108+c51 of dhfr but no additional mutations were classified as
double mutations; samples with mutations in c51+c59+c108 as triple
mutations;sampleswithmutationsinc51+c59+c108ofdhfrand c437
of dhps were considered quadruple mutations; and samples with
mutations in c51+c59+c108 of dhfr and c437+c540 of dhps as
quintuplemutations. For confirmation of the rarec164Lgenotype in
dhfr the PCR-restriction fragment length polymorphism (RFLP)
method described by Duraisingh and others [37] was used.
Statistical methods and sample size considerations
The major objective of the current study was to determine post-
treatment malaria transmission potential in relation to mutations
in the dhfr and dhps genes. This objective was studied using samples
from a previously published drug efficacy trial [27] where the
sample size for transmission experiments was based on the
comparison of transmission potential after SP monotherapy
compared to ACT. In the absence of information on the
prevalence of mutations in the dhfr and dhps genes in the study
area or their expected association with submicroscopic gameto-
cytes and malaria transmission, we based sample size consider-
ations for the current study on previously published studies on the
relation between mutations in the Pfcrt gene and malaria
transmission. Three previously conducted studies included 11–25
membrane-feeding experiments per treatment arm with an
average of 20–30 mosquitoes per experiment [23–25]. We
included samples from 75 membrane-feeding experiments in
randomly selected individuals after SP (n=25), SP+AQ (n=25) or
SP+AS treatment (n=25). Thirty mosquitoes were examined per
experiment, giving a total of 2250 mosquitoes [27,38]. Because
post-treatment gametocytemia and malaria transmission was
previously shown to be similar for SP and SP+AQ [27], data
was grouped as non-ACT (SP mono-therapy and SP+AQ
combination therapy) or ACT (SP+AS) for analyses on the
relation between mutant genotypes and post-treatment gameto-
cytemia and malaria transmission. The transmission potential
during follow-up was quantified as the area under the curve of
Pfs25 QT-NASBA gametocyte density versus time (AUC). This
measure incorporates both the magnitude and the duration of
gametocyte carriage and was described by Mendez and others
[39]. Mosquito transmission experiments were analyzed based on
the proportion of infectious children, the proportion of infected
mosquitoes and oocyst densities in infected mosquitoes.
Statistical analyses were done using SPSS for Windows (version
12.0; SPSS) and Stata (version 8.0; Stata Corporation). Propor-
tions were compared using the x
2 test and the McNemar test for
matched-pair data was used to analyse the directional selection of
mutations from day 0 to day 14. Normally distributed continuous
variables were compared using the Student’s t test. Variables that
were not normally distributed were compared using the Wilcoxon
rank-sum test. The influence of the number of mutations in
infections at enrolment on the proportion of infected mosquitoes at
day 14 was tested using logistic regression models with Generalized
Estimating Equations (GEE); the influence of the number of
mutations in infections at enrolment on oocyst densities in
mosquitoes was determined using negative binomial regression.
Estimates were adjusted for observations from the same individual.
Regression coefficients (b) were calculated with standard errors (se).
Results
Prevalence of mutant dhfr genotypes, enrolment
parasitemia and gametocyte carriage
The relation between mutations in dhfr, enrolment parasitemia,
parasite clearance and post-treatment gametocyte carriage was
determined in baseline samples from 134 individuals treated with SP
or SP+AQ (non-ACT) and 57 individuals treated with SP+AS
(ACT). None of the infections consisted solely of wild-type parasites
at the dhfr locus: all 191samples had the 108N mutation and at least
one additional mutation in c51 (85.9%, 164/191) or c59 (79.6%,
152/191).(TheI164Lsubstitutionatcodon164wasnotevaluated in
these preliminary experiments.) Based on these three codons, 33.5%
(64/191) of the parasite isolates harboured double mutant dhfr loci;
the remaining66.5%(127/191)harbouredinfectionswithmutations
atallthree codons.Intheabsenceofwild-type infections as reference
category, these two groups were compared.
Enrolment asexual parasite density was not related to the number
of dhfr mutations (table 1). Asexual parasites were still detectable on
day 3 after treatment in 14.5% (19/131) of the individuals treated
with non-ACTs and in 1.8% (1/56) of those treated with ACTs
(p,0.001), without a relation with the number of parasite
mutations. Gametocyte prevalence at enrolment was 26.5% (50/
189) by microscopy and 91.4% (118/129) by Pfs25 QT-NASBA,
and was not associated with the number of dhfr mutations.
Transmission potential during follow-up was quantified as the area
under the curve (AUC) of Pfs25 QT-NASBA gametocyte density
versus time for non-ACT and ACT treated children (table 1). The
AUC was significantly lower for ACT compared to non-ACT
treated children (p,0.001). Within the group of non-ACT treated
individuals, AUC was positively associated with the presence of
asexual parasites on day three after treatment (i.e. a longer parasite
clearance time), p=0.046. There was no relation between AUC
and the presence of three mutations in infections for either non-
ACT or ACT treated individuals.
The lack of wild-type dhfr loci among this preliminary baseline
analysis at three codons suggested that it would not be possible to
find associations between parasite genotype and treatment
outcomes of interest such as gametocyte carriage and mosquito
infectivity using this approach. Therefore, in subsequent analyses
we tested for the (rare) substitution of Leucine for isoleucine at
codon 164 of dhfr, and performed a full analysis of the dhps gene at
codons 436, 437, 540, 581 and 613. Significant associations with
treatment outcome and parasite transmissibility have been shown
for mutations at codons 437 [25] and 540 [19].
Prevalence and post-treatment selection of mutant
parasite genotypes in individuals included in
transmission experiments
Seventy-five individuals donated blood for random membrane-
feeding experiments and subsequent QT-NASBA analyses [27].
Fifty-eight of these individuals contributed to parasite DNA
analyses of SNPs in dhfr and dhps at both day 0 and day 14
(figure 1). In this group, dhfr genotyping for day 0 samples was
successful in 100% (58/58) for all codons, except for c59 (57/58).
For the day 14 samples, approximately half of whom were
parasite-negative by microscopy, dhfr genotyping was successful in
71% (41/58) for c51 and c59, in 70% (40/58) for c108 and c164.
SP Resistance and Transmission
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for all codons and for day 14 samples in 47% (27/58) for c436 and
c437 and in 52% (30/58) for c540, c581 and c613. The 164L
mutation was found in four infections, in one case as the majority
(but mixed) genotype and in the other three cases as a mixed
infection. The presence of the 164L mutation was verified by
PCR-RFLP for all four samples.
DNA from 20 individuals in the SP+AQ treatment arm was
available for Pfcrt genotyping. All 20 day 0 samples were
successfully amplified, while only four of the 20 day 14 samples
were amplified even after repeating the procedure. Nineteen of the
twenty day 0 isolates harboured the mutant Pfcrt CVIET
haplotype, and one individual harboured the CVMNK haplotype.
Two of the four day 14 samples carried the CVIET haplotype and
the other two the CVMNK haplotype. The SVMNT haplotype
was not found. The remainder of the analyses will focus on dhfr
and dhps mutations.
Fifteen of the 57 individuals (26.3%) included in the membrane-
feeding experiments had an infection with two mutations in the
dhfr gene at enrolment. The remaining 42 individuals (73.7%) had
infections with three (n=1), four (n=2) or five (n=39) mutations
in the dhfr and dhps genes. Against the background of this high
prevalence prior to treatment, mutations in c59 and c540 were
more common in samples on day 14 after non-ACT treatment;
although this was not statistically significant for either mutation
(figure 1, McNemar test p=0.375 and p=1.00, respectively). The
proportion of infections with $ three mutations did not increase
significantly on day 14 after non-ACT treatment (McNemar test
p=0.687) or after ACT treatment (McNemar test p=0.250).
Mutant genotypes and malaria transmission
The median gametocyte density on day 14 after treatment was
similar for both children harbouring infections with two mutations
in the dhfr and dhps genes and for children with $ three mutations
in these genes. We found no indication that infections with $ three
mutations at enrolment were more transmissible (on day 14 after
treatment) than infections presenting at day 0 with fewer
mutations. The proportion of children infecting at least one
mosquito and infected mosquitoes was similar for both groups
(table 2). Infected mosquitoes (94/1710) harboured 1–13 oocysts.
We observed no statistically significant association between the
presence of $ three mutations and oocyst counts in mosquitoes for
non-ACT treated individuals (b=0.25, se(b)=0.54, p=0.64) or
ACT treated individuals (b=0.16, se(b)=0.73, p=0.82).
The comparison between ACT and non-ACT treated individuals
was previously reported in detail for the entire dataset [27]. There, a
significantly lower proportion of infected mosquitoes following ACT
treatment was observed [27]. The current analyses show that this
observed reduction in transmission potential is evident both for
infections with two mutations in the dhfr and dhps genes and for those
with $ three mutations (table 2). In the current selection of samples,
ACT reduced the median gametocyte density on day of feeding
(p,0.001), the proportion of infected mosquitoes (b=20.86,
se(b)=0.46, p=0.06) and the mean oocyst burden (b=20.89,
se(b)=0.51, p=0.08) compared to non-ACT treatment. However,
we found no evidence this was linked to carriage of mutations in the
dhfr and dhps genes, which was high in all treatment groups.
Discussion
In this study, we observed a high prevalence of mutations in the
dhfrand dhpsgenes ofP. falciparuminan area in western Kenya. None
of the infections harboured fewer than two mutations and the 164L
mutation, which is rare in East Africa [16–19,40], was found in four
infections. Against this background of high prevalence rates of
mutations in the dhfr and dhps genes, and the absence of wild-type
infections to use as comparators, we found no association between
the number of mutations in the dhfr or dhps genes and (sub)micro-
scopic gametocytemia or the infectiousness to mosquitoes.
High prevalences of dhfr and dhps mutations are not uncommon in
East Africa [15,41,42]. In our study population, where we previously
reported that SP monotherapy gave an adequate clinical response in
only 44% of the cases [27], we found that approximately 70% of the
infections prior to treatment harboured dhfr loci with three
mutations. The finding of the 164L mutation is an additional
indication for the high level of SP resistance. There are only a few
other studies that reported the 164L mutation in Africa [15–19]. In
our study, three of the four samples with the 164L mutation also
contained $ three mutations in other codons, indicating that the
next step in the sequence of mutations has been reached. This
suggests that SP treatment efficacy could deteriorate further
[9,13,14] if drug pressure continues and strongly supports the policy
change to AL as first-line antimalarial treatment [1]. Hamel and
others found that the 164L mutation in a high endemic area was not
associated with high-level SP resistance or poor outcome among
adults [40], but the involvement of this mutation in treatment
outcomes for children has yet to be elucidated.
We observed a high prevalence of the Pfcrt mutant CVIET
haplotype, as previously observed in Kenya [43] and Tanzania
[42,44]. A persisting high prevalence of Pfcrt mutant parasites after
abandoning CQ as first line treatment was also reported in central
Table 1. Enrolment characteristics and gametocyte carriage
in relation to mutations in the dhfr gene.
Double mutation
* Three mutations* p-value
Median asexual parasite density at enrolment (IQR)
Non-ACT 10,880 (2,280–31,820) 14,320 (5,020–30,360) 0.27
ACT 12,080 (4,560–39,200) 13,560 (4,020–32,760) 0.99
Proportion of parasitemic children at day 3, % (n/N)
Non-ACT 10.0 (4/40) 16.5 (15/91) 0.33
ACT 4.5 (1/22) 0.0 (0/34) 0.39
Adequate clinical response, % (n/N)
Non-ACT 58.3 (21/36) 63.6 (49/77) 0.59
ACT 71.4 (15/21) 86.7 (26/30) 0.18
Microscopic gametocyte prevalence at enrolment, % (n/N)
Non-ACT 22.5 (9/40) 26.1 (24/92) 0.66
ACT 21.7 (5/23) 35.5 (12/34) 0.27
QT-NASBA gametocyte prevalence at enrolment, % (n/N)
Non-ACT 88.9 (16/18) 91.5 (65/71) 0.66
ACT 87.5 (14/16) 95.8 (23/24) 0.55
Median AUC of QT-NASBA gametocyte density
¥/mL versus time
", (IQR)
Non-ACT 4.23 (0.39–20.14) 6.13 (1.56–15.88) 0.54
ACT 0.17 (0.02–2.82) 0.29 (0.17–82) 0.35
AUC=area under the curve; GM=geometric mean; IQR=interquartile range;
Non-ACT=treatment with sulphadoxine-pyrimethamine (SP) alone or in
combination with amodiaquine; ACT=treatment with SP and artesunate
(3 days).
¥Gametocyte densities were measured by Pfs25 QT-NASBA.
*Mutations were determined at enrolment: double mutation=mutations in
c108+c59 or c108+c51; three mutations=mutations in c51+c59+c108;
"the period from enrolment until time of feeding (day 14) was considered for
determining the AUC.
doi:10.1371/journal.pone.0004364.t001
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other countries [46,47]. The Pfcrt gene is also associated with AQ
resistance [44,48]. AQ was widely used in the study area in
government facilities in the period the study was conducted and
continues to be a popular choice for home treatment with shop-
bought drugs. In the year prior to the current study, we observed
that 30.6% (26/85) of children attending the clinic with
uncomplicated malaria had metabolites of 4-aminoquinolines in
their urine (Bousema, unpublished observations). Although the
used dipstick method could not differentiate between AQ and CQ,
it is likely that the high frequency of the CVIET haplotype is
currently being maintained by the use of AQ, rather than CQ.
Previous studies have found a relation between mutations in the
dhfr and dhps genes and treatment outcome, but only when a
substantial proportion of the parasite population harboured wild-
type alleles [8,21]. This was not the case in our population where
we observed no additional risk of treatment failure for infections
with $ three mutations in the dhfr gene compared to double
mutations. In line with this, the number of parasite mutations was
not related with the proportion of individuals in whom asexual
parasites were still detectable on day 3, an indicator of parasite
clearance time (PCT).
This is the first report that describes the relationship between
submicroscopic gametocytemia and the presence of mutant
genotypes. Mutations in the dhfr gene have previously been
related to an increased microscopic gametocyte prevalence after
SP treatment [20–23]. This observation may be partly explained
by a longer PCT for mutant parasites; this prolonged survival time
under drug pressure allows parasites to invest in transmission
stages [20]. In an earlier study, we have shown that peaks in
microscopic gametocyte prevalence after treatment are likely to be
the result of an increase in the density of gametocytes that were
already present before treatment at submicroscopic concentrations
[49]. We therefore hypothesized that post-treatment gametocyte
density (measured by QT-NASBA) would be increased for
infections with mutations in the dhfr and dhps genes. However,
the complete absence of wild-type infections in our study
population prevented this comparison being made. When using
infections with a double mutation in the dhfr gene as reference
group, we did not observe any association between the presence of
Figure 1. Prevalence of mutant genotypes for dhfr and dhps genes prior to treatment and on day 14 after non-ACT or ACT
treatment in samples included in the membrane-feeding assays. Non-ACT=sulphadoxine-pyrimethamine (SP) alone or in combination with
amodiaquine; ACT=SP in combination with artesunate; $ three mutations=mutations in c51+c59+c108 and possible additional mutations The
number of observations on day 0: all mutations (n=57–58) (see text); on day 14 after non-ACT treatment: c51, c59, c108, c164 (n=33); c436, c437
(n=23); c540, c581, c613 (n=25); $ three mutations (n=33); on day 14 after ACT treatment: c51, c59 (n=8); c108, c164 (n=7); c436, c437 (n=4);
c540, c581, c613 (n=5); $ three mutations (n=7).
doi:10.1371/journal.pone.0004364.g001
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density of submicroscopic gametocytes. The transmission poten-
tial, quantified as the area under the curve of Pfs25 QT-NASBA
gametocyte density versus time, was not associated with additional
mutations compared to the reference group. In line with this, we
also observed no increased malaria transmission measured by
membrane feeding experiments on day 14 after treatment in
relation to additional dhfr/dhps mutations. This contrasts with
studies from the Gambia where a substantial proportion of
parasites carried wild-type Pfcrt alleles. Here, increased transmis-
sion of CQ resistant parasite strains was observed after
examination of a similar number of transmission experiments
and (infected) mosquitoes [23–25]. A recent study from Colombia
also observed that infections with two dhfr mutations (in c108 and
c51) had a 10-fold higher probability of infecting mosquitoes than
infection with wild-type parasites [26].
Limitations
In our study area of moderate transmission intensity, many of
the study participants will have harboured multiple clone
infections. We have presented estimates of mutation prevalence,
and described infections as harbouring two, three or more
mutations. However, in mixed infections individual mutations
may be present on different parasite strains, and so it is not always
possible to confidently infer which haplotypes are present.
None of the infections in our population consisted of pure wild-
type parasites. This is likely to have obscured any relation between
parasite resistance and malaria transmission. Our initial power
calculations were based on assumptions derived from studies
where wild-type samples were used as comparator group [23–25].
Using infections with a double mutation in the dhfr gene as
comparator arm will have reduced our power to detect statistically
significant associations, but allowed us to study the influence of
additional mutations on transmission potential in an area where
no infections contained fewer than two mutations in the dhfr gene.
Barnes and colleagues recently showed a gradual increase in
transmission potential with increasing number of mutations in the
dhfr and dhps genes [22]. Despite the relatively small number of
individuals with the quintuple mutation in that study (n=17), the
study detected a statistically significant 2.6-fold increased AUC
compared to individuals with fewer mutations (n=76) [22]. We
did not observe a similar relation in our population.
Overall evidence
Based on the available literature, it seems plausible that newly-
arising resistance mutations result in a transmission advantage
compared to wild-type parasites under drug pressure. However, in
our study population, where the majority of infections harbour
many resistance-associated mutations in the dhfr and dhps loci, we
found no evidence that parasites with three or more mutations in
the dhfr or dhps genes have an additional transmission advantage
compared to double mutations. Our data also indicate that even at
very high levels of SP resistance, the addition of AS to SP
monotherapy can have a beneficial effect on malaria transmission.
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